COVID-19: TREATMENT OF PATIENTS WITH COVID-19 AT THE PRESENT STAGE
DOI:
https://doi.org/10.11603/1681-2727.2020.3.11548Keywords:
COVID-19, treatmentAbstract
Based on a review of the scientific sources, modern approaches to the treatment of patients with COVID-19 are highlighted. Indications for hospitalization of patients and data on the effectiveness of drugs with different mechanisms of action are shown, taking into account international experience. It is noted that extensive testing of remdezivir, hydroxychloroquine, lopinavir-ritonavir, interferons did not give convincing results. There is hope for the use of convalescents’ plasma and monoclonal antibodies to the virus, which, however, require careful multicenter testing. At the same time, some progress has been made in pathogenetic therapy. The indications, timing and optimal doses of corticosteroids, interleukin inhibitors (tocilizumab), anticoagulants, mainly low molecular weight heparin derivatives, under the control of D-dimer levels and other indicators of hemostasis are clearly substantiated. Antibiotics are recommended for the addition of infrequent bacterial co-infection. The article is addressed mainly to physicians who work with COVID-19 patients.
References
Kupferschmidt, K., & Cohen, J. (2020). Race to find COVID-19 treatments accelerates. Science, 367(6485), 1412-1413. DOI: https://doi.org/10.1126/science.367.6485.1412
Xie, J., Tong, Z., Guan, X., Du, B., Qiu, H., & Slutsky, A. S. (2020). Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive care medicine, 1-4. DOI: https://doi.org/10.1007/s00134-020-05979-7
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., ... & Bannister, R. (2017). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science translational medicine, 9(396). DOI: https://doi.org/10.1126/scitranslmed.aal3653
Grein, J., Ohmagari, N., & Shin, D. (2020).Original: Compassionate Use of Remdesivir for Patients with Severe Covid-19. doi: 10.1056/NEJMoa2007016. DOI: https://doi.org/10.1056/NEJMoa2007016
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., ... & Hu, Y. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236):1569-78.
FDA Approves First Treatment for COVID-19. (2020). https://www.fda.gov. Retrieved from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19?fbclid=IwAR2ApWo5KoG1tSDAEY4B1LPYAXwcbggqI8rfuFYyw368XxTwBox2g7Tthng. DOI: https://doi.org/10.1002/cpu.30542
Preliminary Report of the Favipiravir Observational Study in Japan. (2020). http://www.kansensho.or.jp. Retrieved from: http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf.
Doi, K., Ikeda, M., Hayase, N., Moriya, K., & Morimura, N. (2020). Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Critical Care, 24(1), 1-4. DOI: https://doi.org/10.1186/s13054-020-03078-z
Fact sheet for health care providers emergency use authorization (eua) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of covid-19 in certain hospitalized patients. (2020). https://www.fda.gov. Retrieved from: https://www.fda.gov/media/136537/download.
Sbidian, E., Josse, J., Lemaitre, G., Mayer, I., Bernaux, M., Gramfort, A., ... & Garcelon, N. (2020). Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France. MedRxiv. DOI: 10.1101/2020.06.16.20132597. DOI: https://doi.org/10.1101/2020.06.16.20132597
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., ... & Li, X. (2020). A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine, 382, 1787-1799. DOI: https://doi.org/10.1056/NEJMc2008043
Pan, H., Peto, R., Karim, Q. A., Alejandria, M., Restrepo, A. M. H., Garcia, C. H., ... & Reddy, S. (2020). Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. medRxiv. https://www.medrxiv.org. Retrieved from: https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1?ijkey=20cacba9e914a4fca24a25660e28ee34175f6959&keytype2=tf_ipsecsha.
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., ... & Wei, J. (2020). Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama, 323(16), 1582-1589. DOI: https://doi.org/10.1001/jama.2020.4783
Zeng, Q. L., Yu, Z. J., Gou, J. J., Li, G. M., Ma, S. H., Zhang, G. F., ... & Li, C. (2020). Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. The Journal of infectious diseases, 222(1), 38-43. DOI: https://doi.org/10.1093/infdis/jiaa228
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., ... & Peng, C. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences, 117(17), 9490-9496. DOI: https://doi.org/10.1073/pnas.2004168117
Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., ... & Roh, J. (2020). Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. Journal of Korean medical science, 35(14), e149. DOI: https://doi.org/10.3346/jkms.2020.35.e149
Figlerowicz, M., Mania, A., Lubarski, K., Lewandowska, Z., Służewski, W., Derwich, K., ... & Mazur-Melewska, K. (2020). First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia. Transfusion and Apheresis Science, 102866. DOI: https://doi.org/10.1016/j.transci.2020.102866
Xu, Y., Xu, Z., Liu, X., Cai, L., Zheng, H., Huang, Y., ... & Li, J. (2020). Clinical findings in critical ill patients infected with SARS-Cov-2 in Guangdong Province, China: a multi-center, retrospective, observational study. medRxiv. https://www.medrxiv.org. Retrieved from: http:// medrxiv.org/lookup/doi/10.1101/2020.05.20.20102236. DOI: https://doi.org/10.1101/2020.03.03.20030668
Casadevall, A., & Scharff, M. D. (1995). Return to the past: the case for antibody-based therapies in infectious diseases. Clinical infectious diseases, 21(1), 150-161. DOI: https://doi.org/10.1093/clinids/21.1.150
Casadevall, A., Joyner, M. J., & Pirofski, L. A. (2020). A Randomized Trial of Convalescent Plasma for COVID-19 – Potentially Hopeful Signals. JAMA. https://jamanetwork.com. Retrieved from: https:// jamanetwork.com/journals/jama/fullarticle/2766940. DOI: https://doi.org/10.1001/jama.2020.10218
V Ukraini zavershyly klinichni vyprobuvannia preparatu «Bioven» dlia likuvannia COVID-19 (Clinical trials of Bioven for the treatment of COVID-19 have been completed in Ukraine). (2020). Ukrinform. https://www.ukrinform.ua. Retrieved from: https://www.ukrinform.ua/rubric-society/3136202-v-ukraini-zaversili-klinicni-viprobuvanna-preparatu-bioven-dla-likuvanna-covid19.html.
Кomisaronko, S. (2020). Svitova koronavirusna kryza (World coronavirus crisis). LАТ&K, 120 p. [in Ukrainian].
Christopher, B. (2020). An ACE therapy for COVID-19. Science Translational Medicine. 541(12), DOI: 10.1126/scitranslmed.abb5676. DOI: https://doi.org/10.1126/scitranslmed.abb5676
Kramer. J. (2020). Coronavirus Antibody Therapies Raise Hopes and Skepticism. Scientificamerican. https://www.scientificamerican.com. Retrieved from: https://www.scientificamerican.com/article/coronavirus-antibody-therapies-raise-hopes-and-skepticism1/.
Owence, C. (2020). The good and bad news about coronavirus antibody therapies. Axios. https://www.axios.com. Retrieved from: https://www.axios.com/coronavirus-antibody-treatment-regeneron-cost-availability-e324c8b9-b857-42a8-8472-3b6040163a63.html.
FDA. (2020). Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19. FDA News Release. https://www.fda.gov. Retrieved from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19.
World Health Organization. (2020). Corticosteroids for COVID-19: living guidance, 2 September 2020 (No. WHO/2019-nCoV/Corticosteroids/2020.1). https://www.who.int. Retrieved from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1.
Siemieniuk, R. A., Bartoszko, J. J., Ge, L., Zeraatkar, D., Izcovich, A., Kum, E., ... & Liu, Q. (2020). Drug treatments for covid-19: living systematic review and network meta-analysis. bmj, 370. https://www.bmj.com. Retrieved from: https://www.bmj.com/content/370/bmj.m2980).
Sterne, J. A., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., ... & Dequin, P. F. (2020). Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama. https://jamanetwork.com. Retrieved from: https://jamanetwork.com/journals/jama/article-abstract/2770279)
Lamontagne, F., Agoritsas, T., Macdonald, H., Leo, Y. S., Diaz, J., Agarwal, A., ... & Cao, B. (2020). A living WHO guideline on drugs for covid-19. Bmj, 370. https://www.bmj.com. Retrieved from: https://www.bmj.com/content/370/bmj.m3379.
European Medicines Agency. EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation. (2020). https://www.ema.europa.eu. Retrieved from: https://www.ema.europa.eu/en/news/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-mechanical-ventilation.
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L., Cheng, V. C. C., ... & Shoham, S. (2020). Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clinical Infectious Diseases. https://www.idsociety.org. Retrieved from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. DOI: https://doi.org/10.1093/cid/ciaa478
Aziz, M., Haghbin, H., Sitta, E. A., Nawras, Y., Fatima, R., Sharma, S., ... & Assaly, R. (2020). Efficacy of Tocilizumab in COVID-19: A Systematic review and Meta-Analysis. Journal of Medical Virology. https://onlinelibrary.wiley.com. Retrieved from: https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26509. DOI: https://doi.org/10.1002/jmv.26509
Furlow, B. (2020). COVACTA trial raises questions about tocilizumab’s benefit in COVID-19. The Lancet Rheumatology, 2(10), e592. DOI: https://doi.org/10.1016/S2665-9913(20)30313-1
National Institutes of Health. (2020). Coronavirus disease 2019 (COVID-19) treatment guidelines. https://www.covid19treatmentguidelines.nih.gov. Retrieved from: https://www.covid19treatmentguidelines.nih.gov/whats-new/
Cavalli, G., De Luca, G., Campochiaro, C., Della-Torre, E., Ripa, M., Canetti, D., ... & Tomelleri, A. (2020). Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology. https://www.ncbi.nlm.nih.gov/Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252085/. DOI: https://doi.org/10.1016/S2665-9913(20)30127-2
Navarro-Millán, I., Sattui, S. E., Lakhanpal, A., Zisa, D., Siegel, C. H., & Crow, M. K. (2020). Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis & Rheumatology. https://onlinelibrary.wiley.com. Retrieved from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41422. DOI: https://doi.org/10.1002/art.41422
National Institute for Health and Care Excellence. (2020). COVID 19 rapid evidence summary: anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis. 2020. https://www.nice.org.uk. Retrieved from: https://www.nice.org.uk/advice/es26/chapter/Key-messages.
Barnes, G. D., Burnett, A., Allen, A., Blumenstein, M., Clark, N. P., Cuker, A., ... & Kaatz, S. (2020). Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis, 1. https://link.springer.com. Retrieved from: https://link.springer.com/article/10.1007/s11239-020-02138-z. DOI: https://doi.org/10.1007/s11239-020-02138-z
Moores, L. K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J. F., Doerschug, K., ... & Wells, P. (2020). Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest, 158(3), 1143-1163. DOI: https://doi.org/10.1016/j.chest.2020.05.559
American Society Of Hematology. COVID-19 and VTE/anticoagulation: frequently asked questions. (2020). https://www.hematology.org. Retrieved from: https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation.
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., ... & Tang, L. V. (2020). COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 75(23), 2950-2973. DOI: https://doi.org/10.1016/j.jacc.2020.04.031
World Health Organization. (2020). Clinical management of COVID-19: interim guidance, 27 May 2020 (No. WHO/2019-nCoV/clinical/2020.5). https://www.who.int. Retrieved from: https://www.who.int/publications/i/item/clinical-management-of-covid-19.
Nadkarni, G. N., Lala, A., Bagiella, E., Chang, H. L., Moreno, P., Pujadas, E., ... & Cordon-Cardo, C. (2020). Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: a single health system study. Journal of the American College of Cardiology. https://www.ncbi.nlm.nih.gov. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449655/. DOI: https://doi.org/10.1016/j.jacc.2020.08.041
Boretti, A., & Banik, B. K. (2020). Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition, 100190. https://www.ncbi.nlm.nih.gov. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172861/. DOI: https://doi.org/10.1016/j.phanu.2020.100190
Vitamin, C. (2020). infusion for the treatment of severe 2019-nCOV infected pneumonia. https://clinicaltrials.gov. Retrieved from: https://clinicaltrials.gov/ct2/show/NCT04264533. Accessed April, 16.
Grant, W. B., Lahore, H., McDonnell, S. L., Baggerly, C. A., French, C. B., Aliano, J. L., & Bhattoa, H. P. (2020). Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients, 12(4), 988. DOI: https://doi.org/10.3390/nu12040988
Vitamin D on prevention and treatment of COVID-19 (COVITD-19). (2020). https://clinicaltrials.gov . Retrieved from: https://clinicaltrials.gov/ct2/show/NCT04334005.
Castillo, M. E., Costa, L. M. E., Barrios, J. M. V., Díaz, J. F. A., Miranda, J. L., Bouillon, R., & Gomez, J. M. Q. (2020). Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. The Journal of steroid biochemistry and molecular biology, 203, 105751. DOI: https://doi.org/10.1016/j.jsbmb.2020.105751
National Institute for Health and Care Excellence. (2020). COVID-19 rapid evidence summary: vitamin D for COVID-19. https://www.nice.org.uk. Retrieved from: https://www.nice.org.uk/advice/es28/chapter/Key-messages.
Dhar, D., & Mohanty, A. (2020). Gut microbiota and Covid-19-possible link and implications. Virus Research, 198018. https://www.sciencedirect.com. Retrieved from: https://www.sciencedirect.com/science/article/pii/S0168170220304603?via%3Dihub. DOI: https://doi.org/10.1016/j.virusres.2020.198018
Mak, J. W., Chan, F. K., & Ng, S. C. (2020). Probiotics and COVID-19–Authors’ reply. The Lancet Gastroenterology & Hepatology, 5(8), 722-723. DOI: https://doi.org/10.1016/S2468-1253(20)30197-7
Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease. (2020). https://www.cdc.gov. Retrieved from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.
Andreychyn, M. A., Nychyk, N. A., Zavidniuk, N. H., Iosyk, I. I., Ischuk, I. S., & Ivakhiv, O. L. (2020). COVID-19: epidemiolohiia, klinika, diahnostyka, likuvannia ta profilaktyka (COVID-19: epidemiology, clinic, diagnostics, treatment and prevention). Infektsiini khvoroby, (2), 41-55. [in Ukrainian].
National Institute for Health and Care Excellence. (2020). COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. https://www.nice.org.uk. Retrieved from: https://www.nice.org.uk/guidance/ng173.
Metlay, J. P., & Waterer, G. W. (2020). Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic. https://www.acpjournals.org. Retrieved from: https://www.acpjournals.org/doi/10.7326/M20-2189. DOI: https://doi.org/10.7326/M20-2189
Antimicrobial Stewardship in COVID-19. (2020). https://www.hpsc.ie. Retrieved from: ttps://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/guidance/infectionpreventionandcontrolguidance/antimicrobialstewardship/Antimicrobial%20Stewardship%20in%20COVID%2019.pdf.
COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community. (2020). https://www.nice.org.uk. Retrieved from: https://www.nice.org.uk/guidance/ng165/resources/covid19-rapid-guideline-managing-suspected-or-confirmed-pneumonia-in-adults-in-the-community-pdf-66141902429125.
Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. (2020). https://www.mp.pl. Retrieved from: https://www.mp.pl/paim/en/node/15270/pdf.
Clinical management of patients with COVID-19: Second interim guidance. (2020). https://www.canada.ca. Retrieved from: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/clinical-management-covid-19.html.
Protocolul de tratament al infecției cu virusul SARS-Cov-2, din 26.03.2020. https://www.cnscbt.ro. Retrieved from: https://www.cnscbt.ro/index.php/legislatie_cov/1617-protocolul-de-tratament-covid-19/file.
Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. (2020). https://www.who.int. Retrieved from: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf.
Nakaz MOZ Ukrainy vid 11.11.2020 № 2583 “Pro vnesennia zmin do Standartiv medychnoi dopomohy “Koronavirusna khvoroba (COVID-19)” [Order of the Ministry of Health of Ukraine dated 11.11.2020 No. 2583 “On Amendments to the Standards of Medical Care “Coronavirus Disease (COVID-19)”]. zakon.rada.gov.ua. Retrieved from: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-11112020--2583-pro-vnesennja-zmin-do-protokolu--nadannja-medichnoi-dopomogi-dlja-likuvannja--koronavirusnoi-hvorobi-covid-19 [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
